Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation.

Satoshi Kimura, Kensuke Egashira, Kaku Nakano, Eiko Iwata, Miho Miyagawa, Hiroyuki Tsujimoto, Kaori Hara, Yoshiaki Kawashima, Ryuji Tominaga, Kenji Sunagawa

研究成果: ジャーナルへの寄稿記事

37 引用 (Scopus)

抄録

BACKGROUND: Clinical outcome of surgical revascularization using autologous vein graft is limited by vein graft failure attributable to neointima formation. Platelet-derived growth factor (PDGF) plays a central role in the pathogenesis of vein graft failure. Therefore, we hypothesized that nanoparticle (NP)-mediated drug delivery system of PDGF-receptor (PDGF-R) tyrosine kinase inhibitor (imatinib mesylate: STI571) could be an innovative therapeutic strategy. METHODS AND RESULTS: Uptake of STI571-NP normalized PDGF-induced cell proliferation and migration. Excised rabbit jugular vein was treated ex vivo with PBS, STI571 only, FITC-NP, or STI571-NP, then interposed back into the carotid artery position. NP was detected in many cells in the neointima and media at 7 and 28 days after grafting. Significant neointima was formed 28 days after grafting in the PBS group; this neointima formation was suppressed in the STI571-NP group. STI571-NP treatment inhibited cell proliferation and phosphorylation of the PDGF-R-beta but did not affect inflammation and endothelial regeneration. CONCLUSIONS: STI571-NP-induced suppression of vein graft neointima formation holds promise as a strategy for preventing vein graft failure.

元の言語英語
ジャーナルCirculation
118
発行部数14 Suppl
DOI
出版物ステータス出版済み - 1 1 2008

Fingerprint

Neointima
Nanoparticles
Veins
Transplants
Platelet-Derived Growth Factor
Cell Proliferation
Imatinib Mesylate
Fluorescein-5-isothiocyanate
Jugular Veins
Drug Delivery Systems
Carotid Arteries
Cell Movement
Regeneration
Phosphorylation
Rabbits
Inflammation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

これを引用

Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. / Kimura, Satoshi; Egashira, Kensuke; Nakano, Kaku; Iwata, Eiko; Miyagawa, Miho; Tsujimoto, Hiroyuki; Hara, Kaori; Kawashima, Yoshiaki; Tominaga, Ryuji; Sunagawa, Kenji.

:: Circulation, 巻 118, 番号 14 Suppl, 01.01.2008.

研究成果: ジャーナルへの寄稿記事

Kimura, S, Egashira, K, Nakano, K, Iwata, E, Miyagawa, M, Tsujimoto, H, Hara, K, Kawashima, Y, Tominaga, R & Sunagawa, K 2008, 'Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation.', Circulation, 巻. 118, 番号 14 Suppl. https://doi.org/10.1161/CIRCULATIONAHA.107.740613
Kimura, Satoshi ; Egashira, Kensuke ; Nakano, Kaku ; Iwata, Eiko ; Miyagawa, Miho ; Tsujimoto, Hiroyuki ; Hara, Kaori ; Kawashima, Yoshiaki ; Tominaga, Ryuji ; Sunagawa, Kenji. / Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. :: Circulation. 2008 ; 巻 118, 番号 14 Suppl.
@article{9fe2e26453a94a2fb0867cc2523ced7f,
title = "Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation.",
abstract = "BACKGROUND: Clinical outcome of surgical revascularization using autologous vein graft is limited by vein graft failure attributable to neointima formation. Platelet-derived growth factor (PDGF) plays a central role in the pathogenesis of vein graft failure. Therefore, we hypothesized that nanoparticle (NP)-mediated drug delivery system of PDGF-receptor (PDGF-R) tyrosine kinase inhibitor (imatinib mesylate: STI571) could be an innovative therapeutic strategy. METHODS AND RESULTS: Uptake of STI571-NP normalized PDGF-induced cell proliferation and migration. Excised rabbit jugular vein was treated ex vivo with PBS, STI571 only, FITC-NP, or STI571-NP, then interposed back into the carotid artery position. NP was detected in many cells in the neointima and media at 7 and 28 days after grafting. Significant neointima was formed 28 days after grafting in the PBS group; this neointima formation was suppressed in the STI571-NP group. STI571-NP treatment inhibited cell proliferation and phosphorylation of the PDGF-R-beta but did not affect inflammation and endothelial regeneration. CONCLUSIONS: STI571-NP-induced suppression of vein graft neointima formation holds promise as a strategy for preventing vein graft failure.",
author = "Satoshi Kimura and Kensuke Egashira and Kaku Nakano and Eiko Iwata and Miho Miyagawa and Hiroyuki Tsujimoto and Kaori Hara and Yoshiaki Kawashima and Ryuji Tominaga and Kenji Sunagawa",
year = "2008",
month = "1",
day = "1",
doi = "10.1161/CIRCULATIONAHA.107.740613",
language = "English",
volume = "118",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "14 Suppl",

}

TY - JOUR

T1 - Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation.

AU - Kimura, Satoshi

AU - Egashira, Kensuke

AU - Nakano, Kaku

AU - Iwata, Eiko

AU - Miyagawa, Miho

AU - Tsujimoto, Hiroyuki

AU - Hara, Kaori

AU - Kawashima, Yoshiaki

AU - Tominaga, Ryuji

AU - Sunagawa, Kenji

PY - 2008/1/1

Y1 - 2008/1/1

N2 - BACKGROUND: Clinical outcome of surgical revascularization using autologous vein graft is limited by vein graft failure attributable to neointima formation. Platelet-derived growth factor (PDGF) plays a central role in the pathogenesis of vein graft failure. Therefore, we hypothesized that nanoparticle (NP)-mediated drug delivery system of PDGF-receptor (PDGF-R) tyrosine kinase inhibitor (imatinib mesylate: STI571) could be an innovative therapeutic strategy. METHODS AND RESULTS: Uptake of STI571-NP normalized PDGF-induced cell proliferation and migration. Excised rabbit jugular vein was treated ex vivo with PBS, STI571 only, FITC-NP, or STI571-NP, then interposed back into the carotid artery position. NP was detected in many cells in the neointima and media at 7 and 28 days after grafting. Significant neointima was formed 28 days after grafting in the PBS group; this neointima formation was suppressed in the STI571-NP group. STI571-NP treatment inhibited cell proliferation and phosphorylation of the PDGF-R-beta but did not affect inflammation and endothelial regeneration. CONCLUSIONS: STI571-NP-induced suppression of vein graft neointima formation holds promise as a strategy for preventing vein graft failure.

AB - BACKGROUND: Clinical outcome of surgical revascularization using autologous vein graft is limited by vein graft failure attributable to neointima formation. Platelet-derived growth factor (PDGF) plays a central role in the pathogenesis of vein graft failure. Therefore, we hypothesized that nanoparticle (NP)-mediated drug delivery system of PDGF-receptor (PDGF-R) tyrosine kinase inhibitor (imatinib mesylate: STI571) could be an innovative therapeutic strategy. METHODS AND RESULTS: Uptake of STI571-NP normalized PDGF-induced cell proliferation and migration. Excised rabbit jugular vein was treated ex vivo with PBS, STI571 only, FITC-NP, or STI571-NP, then interposed back into the carotid artery position. NP was detected in many cells in the neointima and media at 7 and 28 days after grafting. Significant neointima was formed 28 days after grafting in the PBS group; this neointima formation was suppressed in the STI571-NP group. STI571-NP treatment inhibited cell proliferation and phosphorylation of the PDGF-R-beta but did not affect inflammation and endothelial regeneration. CONCLUSIONS: STI571-NP-induced suppression of vein graft neointima formation holds promise as a strategy for preventing vein graft failure.

UR - http://www.scopus.com/inward/record.url?scp=54449083089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449083089&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.107.740613

DO - 10.1161/CIRCULATIONAHA.107.740613

M3 - Article

VL - 118

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 14 Suppl

ER -